CV
CVM.US CEL-SCI Corp
- Market cap
- USD 22.5M
- P/E
- -
- P/B
- 1.91x
- ROE
- -202.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is CVM.US undervalued?
Graham numberThe Graham number of CEL-SCI Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CEL-SCI Corp fundamental analysis
No fundamental analysis for CEL-SCI Corp yet.
CEL-SCI Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates t…
Full company profileCEL-SCI Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CEL-SCI Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 285K | 69.0K | 477K | 463K | 559K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 268K | -564K | 466K | 450K | -17.3M | -499K | -3.88M | -22.5M | -3.97M | -15.9M | -7.44M |
| Operating Income | -25.6M | -21.3M | -16.8M | -20.2M | -29.0M | -36.2M | -36.1M | -31.5M | -26.4M | -24.8M | -21.7M |
| EBITDA | -24.1M | -20.8M | -16.1M | -19.7M | -26.8M | -33.0M | -31.8M | -27.5M | -22.2M | -20.9M | -17.9M |
| Net Income | -11.5M | -14.4M | -31.8M | -24.7M | -30.3M | -36.4M | -36.7M | -32.4M | -26.9M | -25.4M | -22.1M |
| EPS | -2.36 | -1.82 | -1.87 | -0.79 | -25 | -27 | -26 | -22 | -14 | -6.27 | -1.83 |
| Balance Sheet | |||||||||||
| Total Assets | 11.6M | 22.9M | 29.6M | 27.6M | 40.5M | 75.9M | 50.5M | 30.5M | 27.0M | 28.2M | 21.4M |
| Total Liabilities | 12.6M | 26.3M | 29.6M | 22.5M | 20.8M | 19.3M | 18.4M | 17.3M | 14.1M | 12.2M | 10.4M |
| Shareholders' Equity | -956K | -3.34M | 916.00 | 5.13M | 19.7M | 56.5M | 32.2M | 13.2M | 12.9M | 16.0M | 11.0M |
| Cash & Short-term Investments | 2.92M | 2.37M | 10.3M | 8.44M | 15.5M | 42.2M | 22.7M | 4.15M | 4.74M | 11.0M | 6.53M |
| Total Debt | 13.3M | 14.2M | 14.2M | 13.6M | 13.9M | 16.0M | 15.3M | 13.6M | 11.6M | 9.38M | 7.89M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -23.1M | -13.8M | -13.4M | -16.3M | -15.3M | -18.8M | -18.2M | -22.8M | -18.8M | -17.1M | -16.1M |
| Capital Expenditure | 34.2K | 17.0K | 58.1K | 336K | 2.69M | 9.04M | 638K | 372K | 94.9K | 38.1K | 12.00 |
| Free Cash Flow | -23.1M | -13.8M | -13.4M | -16.7M | -18.0M | -27.8M | -18.9M | -23.2M | -18.9M | -17.2M | -16.1M |
| Ratios | |||||||||||
| ROE | - | - | -3,475,677.4% | -481.0% | -153.5% | -64.3% | -114.1% | -244.9% | -209.2% | -159.2% | -202.1% |
| ROA | -98.9% | -62.7% | -107.6% | -89.4% | -74.7% | -47.9% | -72.6% | -106.0% | -99.7% | -90.3% | -103.7% |
| Net Profit Margin | -4,022.6% | -20,810.3% | -6,680.7% | -5,336.0% | -5,419.5% | - | - | - | - | - | - |
| Debt to Equity | - | - | 15,527.75x | 2.66x | 0.71x | 0.28x | 0.48x | 1.03x | 0.90x | 0.59x | 0.72x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CEL-SCI Corp dividends
CEL-SCI Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on May 20, 2025.
Who owns CEL-SCI Corp
- Insiders 3.72%
- Institutions 14.49%
- Public & others 81.79%
- Shares outstanding 17.6M
- Free float 16.9M
CEL-SCI Corp company profile
- Company name
- CEL-SCI Corp
- Ticker
- CVM.US
- Exchange
- USA Stocks
- Listed since
- Jan 1, 1987
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- September
- Address
- 8229 Boone Boulevard, Vienna, VA, United States, 22182
- Phone
- 703 506 9460
- Website
- cel-sci.com
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
CEL-SCI Corp management
4- Mr. Geert R. Kersten Esq.CEO, CAO,Treasurer and Director · born 1959
- Ms. Patricia B. PrichepChief Financial & Operations Officer, Compliance Officer & Corporate Secretary · born 1951
- Dr. Eyal Talor Ph.D.Chief Scientific Officer · born 1956
- Mr. John CiprianoSenior Vice President of Regulatory Affairs · born 1942